~~cholestanylamine~~cholesteryl amine.

[Claim 16] The double-stranded oligo RNA molecule(s) of claim 14, wherein the glyceride derivative is selected from mono-, di-, and tri-glycerides.

[Claim 17] The double-stranded oligo RNA molecule(s) of any one of claims 7 to 16, wherein the covalent bond represented by X and Y is a non-degradable bond or a degradable bond.

[Claim 18] The double-stranded oligo RNA molecule(s) of claim 17, wherein the non-degradable bond is an amide bond or a phosphate bond.

[Claim 19] The double-stranded oligo RNA molecule(s) of claim 17, wherein the degradable bond is a disulfide bond, an acid-degradable bond, an ester bond, an anhydride bond, a biodegradable bond, or an enzyme-degradable bond.

[Claim 20] The double-stranded oligo RNA molecule(s) of any one of claims 7 to 16, wherein a ligand which binds to a receptor promoting internalization into target cells through receptor-mediated endocytosis (REM) is additionally bound to the hydrophilic compound.

[Claim 21] The double-stranded oligo RNA molecule(s) of claim 20, wherein the ligand is selected from a group consisting of a target receptor-specific antibody, aptamer, peptide, folate, N-acetyl galactosamine (NAG), glucose, and mannose.

[Claim 22] Nanoparticle(s) comprising the double-stranded oligo RNA molecule(s) of any one of claims 7 to 21.

[Claim 23] The nanoparticle(s) of claim 22, wherein it is composed by mixing double-stranded oligo RNA molecules containing siRNAs comprising different sequences with each other.

[Claim 24] A pharmaceutical composition comprising the siRNA of any one of claims 1 to 6, the double-stranded oligo RNA molecule(s) of any one of claims 7 to 21, or the nanoparticle(s) of any one of claims 22 to 23 as an active ingredient.

[Claim 25] The pharmaceutical composition of claim 24, wherein it is a pharmaceutical composition for preventing or treating cancer.

[Claim 26] The pharmaceutical composition of claim 25, wherein cancer is selected from a group consisting of liver cancer, gastric cancer, colon cancer, pancreatic cnacer, prostate cancer, breast cancer, ovarian cancer, kidney cancer, and lung cancer.

[Claim 27] The pharmaceutical composition of claim 26, wherein liver cancer is hepatocellular carcinoma (HCC).

[Claim 28] Lypholized formulations comprising the pharmaceutical composition of